- Home
- ABVC vs LTRN Comparison
ABVC vs LTRN Comparison
Compare ABVC & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | LTRN |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 49.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ABVC | LTRN |
|---|---|---|
| Price | $2.08 | $3.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 68.8K | ★ 71.4K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $797,916.00 | N/A |
| Revenue This Year | $735.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 56.52 | N/A |
| 52 Week Low | $0.40 | $2.55 |
| 52 Week High | $5.48 | $6.12 |
Technical Indicators
Market Signals| Indicator | ABVC | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 40.38 |
| Support Level | $2.06 | $3.72 |
| Resistance Level | $2.30 | $3.98 |
| Average True Range (ATR) | 0.17 | 0.26 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 12.71 | 10.67 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.